The GHRH receptor activates a JAK2/STAT3 inflammatory cascade in eye tissue, and blocking this pathway with a GHRH antagonist or JAK inhibitor reduced acute uveitis in rats.
JAK2-specificGHRH-R directly interacts with JAK2 (not JAK1, JAK3, or TYK2) to drive ocular inflammation
What the researchers found
GHRH-R specifically activates JAK2/STAT3 signaling in ocular inflammation; both the GHRH-R antagonist MIA-602 and JAK inhibitor ruxolitinib reduced acute uveitis.
Why it matters
Uveitis is a leading cause of blindness with limited treatment options. Identifying GHRH-R as a druggable inflammatory mediator in the eye opens new therapeutic avenues.
The numbers in context
GHRH-R → JAK2 → STAT3 → IL-6/IL-17A/COX2/iNOS; MIA-602 suppressed STAT3; ruxolitinib partially alleviated uveitis in vivo
How the study worked
Multi-model approach: human ciliary epithelial cells, rat iris/ciliary body explants, and in vivo rat endotoxin-induced uveitis. Methods included co-immunoprecipitation, bioinformatics, phosphorylation assays, and inflammatory marker quantification.
Who was studied
Rat endotoxin-induced uveitis model; human ciliary epithelial cells; iris/ciliary body explants
What this study cannot tell us
Rat model of endotoxin-induced uveitis may not fully represent autoimmune uveitis in humans; ruxolitinib only partially alleviated inflammation; MIA-602 not tested in vivo in this study.
How to read the evidence
Moderate — comprehensive multi-model mechanistic study with human cell validation, but partial efficacy in vivo.
When this study was published
Published in 2020; JAK inhibitors for eye disease have gained interest since.
The bigger picture
GHRH-R antagonists are being developed for cancer. This study reveals an unexpected application in eye inflammation, potentially expanding the clinical utility of this drug class.
Questions still open
- Would topical eye drops containing GHRH-R antagonists be effective for uveitis?
- Is the GHRH-R/JAK2/STAT3 axis also active in chronic/autoimmune uveitis?
- Could existing JAK inhibitors already in use for rheumatoid arthritis be repurposed for uveitis?
Common questions
What is uveitis?
How does a growth hormone receptor cause eye inflammation?
Read the original research
Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.
Proceedings of the National Academy of Sciences of the United States of America, 117(11), 6067-6074
Citation
Liang, Wei Cheng; Ren, Jia Lin; Yu, Qiu Xiao; Li, Jian; Ng, Tsz Kin; Chu, Wai Kit; Qin, Yong Jie; Chu, Kai On; Schally, Andrew V; Pang, Chi Pui; Chan, Sun On. (2020). Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.. Proceedings of the National Academy of Sciences of the United States of America, 117(11), 6067-6074. https://doi.org/10.1073/pnas.1904532117